Fig. 4
Marked differences between the prescribed carboplatin dosages and hypothetical carboplatin dosages. A-D MDRD-, CKD-EPI 2009-, and CKD-EPI 2021-based hypothetical carboplatin doses were compared to those that are based on the CG formula. Percent changes are displayed on heatmaps. Patients who would have received a lower dose based on MDRD, CKD-EPI 2009 and/or CKD-EPI 2021are shown with red boxes. Those who would have received a higher dose are shown with blue boxes. These two patient groups are indicated by vertical dashed or solid brackets. Grey boxes indicate a carboplatin cycle that was not administered. The intensity of the colours depicts the degree of change, and shown with a colour scale below the heatmaps. A Carboplatin changes for all AUC-5/6 patients. Carboplatin cycle numbers are displayed at the top of the heatmap. The name of each formula is indicated below the carboplatin cycle numbers. C-E 2009 and C-E 2021 stand for CKD-EPI 2009 and CKD-EPI 2021, respectively. B-D Carboplatin changes for the patients who would have received a dose that is at least 20% different than their original dose in any of the six carboplatin cycles as a result of substituting CG with MDRD (B), CKD-EPI 2009 (C), and CKD-EPI 2021 (D). Red boxes indicate Carbo High patients, and blue boxes indicate Carbo Low patients. See Supplementary Fig. 2 for AUC-2 data